Second-generation tyrosine kinase inhibitors as first-line treatment strategy in newly diagnosed chronic phase chronic myeloid leukemia patients

Current Cancer Drug Targets

Volumn 12, Issue 4, 2012, Pages 391-401

  Breccia, M ^a   Alimena, G ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Chronic myeloid leukemia; Dasatinib; First line; Imatinib; Nilotinib

Indexed keywords

ABC TRANSPORTER A1; ABC TRANSPORTER G1; ABELSON KINASE; ALANINE AMINOTRANSFERASE; AMYLASE; ASPARTATE AMINOTRANSFERASE; BCR ABL PROTEIN; BILIRUBIN; BOSUTINIB; BREAST CANCER RESISTANCE PROTEIN; CYTARABINE; DASATINIB; EPHRIN; GLUCOSE; IMATINIB; INTERFERON; NILOTINIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR; TRIACYLGLYCEROL LIPASE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; AMYLASE BLOOD LEVEL; ANEMIA; AREA UNDER THE CURVE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BONE PAIN; CANCER GROWTH; CANCER RESISTANCE; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CYTOPENIA; DIABETIC KETOACIDOSIS; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPNEA; EDEMA; FATIGUE; FLUID RETENTION; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; GLUCOSE BLOOD LEVEL; HEADACHE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERGLYCEMIA; HYPOPHOSPHATEMIA; ISCHEMIC HEART DISEASE; LEUKOCYTE COUNT; LIVER TOXICITY; MUSCULOSKELETAL PAIN; MYALGIA; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; OVERALL SURVIVAL; PANCREATITIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLEURA EFFUSION; PROGRESSION FREE SURVIVAL; QT INTERVAL; RASH; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; VOMITING;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; SRC-FAMILY KINASES; THIAZOLES; TREATMENT OUTCOME;

EID: 84860282545     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/156800912800190965     Document Type: Review

References (40)

1. de Lavallade, H.; Apperley, J. F.; Khorashad, J. S.; Milojkovic, D.; Reid, A. G.; Bua, M.; Szydlo, R.; Olavarria, E.; Kaeda, J.; Goldman, J. M.; Marin, D. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J. Clin. Oncol. 2008, 26 (20), 3358-3363.
2. Druker, B. J.; Guilhot, F.; O'Brien, S. G.; Gathmann, I.; Kantarjian, H.; Gattermann, N.; Deininger, M. W.; Silver, R. T.; Goldman, J. M.; Stone, R. M.; Cervantes, F.; Hochhaus, A.; Powell, B. L.; Gabrilove, J. L.; Rousselot, P.; Reiffers, J.; Cornelissen, J. J.; Hughes, T.; Agis, H.; Fischer, T.; Verhoef, G.; Shepherd, J.; Saglio, G.; Gratwohl, A.; Nielsen, J. L.; Radich, J. P.; Simonsson, B.; Taylor, K.; Baccarani, M.; So, C.; Letvak, L.; Larson, R. A.; IRIS Investigators. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. 2006, 355 (23), 2408-2417.
3. Quintás-Cardama, A.; Kantarjian, H.; Jones, D.; Shan, J.; Borthakur, G.; Thomas, D.; Kornblau, S.; O'Brien, S.; Cortes, J. Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving highdose or standard-dose imatinib therapy. Blood 2009, 113 (25), 6315-6321.
4. Baccarani, M.; Cortes, J.; Pane, F.; Niederwieser, D.; Saglio, G.; Apperley, J.; Cervantes, F.; Deininger, M.; Gratwohl, A.; Guilhot, F.; Hochhaus, A.; Horowitz, M.; Hughes, T.; Kantarjian, H.; Larson, R.; Radich, J.; Simonsson, B.; Silver, R. T.; Goldman, J.; Hehlmann, R.; European LeukemiaNet. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J. Clin. Oncol. 2009, 27 (35), 6041-6051.
5. Marin, D.; Bazeos, A.; Mahon, F. X.; Eliasson, L.; Milojkovic, D.; Bua, M.; Apperley, J. F.; Szydlo, R.; Desai, R.; Kozlowski, K.; Paliompeis, C.; Latham, V.; Foroni, L.; Molimard, M.; Reid, A.; Rezvani, K.; de Lavallade, H.; Guallar, C.; Goldman, J.; Khorashad, J. S. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J. Clin. Oncol. 2010, 28 (14), 2381-2388.
6. Ibrahim, A. R.; Eliasson, L.; Apperley, J. F.; Milojkovic, D.; Bua, M.; Szydlo, R.; Mahon, F. X.; Kozlowsk, K.; Paliompeis, C.; Foroni, L.; Khorashad, J. S.; Bazeos, A.; Molimard, M.; Reid, A.; Rezvani, K.; Gerrard, G.; Goldman, J.; Marin, D. Poor adherence is the main reason for loss of CCyR and imatinib failure for CML patients on long term therapy. Blood 2011, 117 (14), 3733-3736.
7. Keam, S. J. Dasatinib: in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. BioDrugs 2008, 22 (1), 59-69.
8. Jabbour, E.; Cortes, J.; Kantarjian, H. Dasatinib for the treatment of Philadelphia chromosome-positive leukemias. Expert. Opin. Investig. Drugs 2007, 16 (85), 679-687.
9. Steinberg, M. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukaemia and Philadelphia chromosome positive acute lymphoblastic leukaemia. Clin. Ther. 2007, 29 (11), 2289-2308.
10. Breccia, M.; Alimena, G. Activity and safety of dasatinib as second line treatment or in newly diagnosed chronic phase chronic myeloid leukemia patients. BioDrugs 2011, 25 (3), 147-157.
11. Nam, S.; Williams, A.; Vultur, A.; List, A.; Bhalla, K.; Smith, D.; Lee, F. Y.; Jove, R. Dasatinib (BMS-354825) inhibits Stat5 signalling associated with apoptosis in chronic myelogenous leukemia cells. Mol. Cancer Ther. 2007, 6 (4), 1400-1405.
12. Condorelli, F.; Genazzani, A. A. Dasatinib: is it all in the dose? BioDrugs 2010, 24 (3), 157-163.
13. Hochhaus, A. Dasatinib for the treatment of Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib failure. Expert. Opin. Pharmacother. 2007, 8 (18), 3257-3264.
14. Lindauer, M.; Hochhaus, A. Dasatinib. Recent Results Cancer Res. 2010, 184, 83-102.
15. Aleshin, A.; Finn, R. S. SRC: a century of science brought to the clinic. Neoplasia 2010, 12 (8), 599-607.
16. Muller, M. C.; Cortes, J. E.; Kim, D. W.; Druker, B. J.; Erben, P.; Pasquini, R.; Branford, S.; Hughes, T. P.; Radich, J. P.; Ploughman, L.; Mukhopadhyay, J.; Hochhaus, A. Dasatinib treatment of chronic phase chronic myeloid leukemia: analysis of responses according to pre-existing BCR-ABL mutations. Blood 2009, 114, 4944-4953.
17. Manley, P. W.; Stiefl, N.; Cowan-Jacob, S. W.; Kaufmann, S.; Mestan, J.; Wartmann, M.; Wiesmann, M.; Woodman, R.; Gallagher, N. Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib. Bioorg. Med. Chem. 2010, 18 (19), 6977-6986.
18. Manley, P. W.; Cowan-Jacob, S. W.; Mestan, J. Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia. Biochim. Biophys. Acta 2005, 1754, 3-13.
19. Liu, Y.; Gray, N. S. Rational design of inhibitors that bind to inactive kinase conformations. Nat. Chem. Biol. 2006, 2 (7), 358-364.
20. Fullmer, A.; Kantarjian, H.; Cortes, J.; Jabbour, E. Nilotinib for the treatment of Philadelphia-chromosome-positive chronic myeloid leukemia. Expert Opin. Pharmacother. 2010, 11 (18), 3065-3072.
21. Breccia, M.; Alimena, G. Nilotinib: a second-generation tyrosine kinase inhibitor for chronic myeloid leukemia. Leuk. Res. 2010, 34 (2), 129-134.
22. Mahon, F. X.; Hayette, S.; Lagarde, V.; Belloc, F.; Turcq, B.; Nicolini, F.; Belanger, C.; Manley, P. W.; Leroy, C.; Etienne, G.; Roche, S.; Pasquet, J. M. Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression. Cancer Res. 2008, 68 (23), 9809-9816.
23. Manley, P. W.; Drueckes, P.; Fendrich, G.; Furet, P.; Liebetanza, J.; Martiny-Baron, G.; Mestan, J.; Trappe, J.; Wartmann, M.; Fabbro, D. Extended kinase profile and properties of the protein kinase inhibitor nilotinib. Biochim. Biophys. Acta 2010, 1804 (3), 445-453.
24. Weisberg, E.; Manley, P. W.; Breitenstein, W.; Brüggen, J.; Cowan-Jacob, S. W.; Ray, A.; Huntly, B.; Fabbro, D.; Fendrich, G.; Hall-Meyers, E.; Kung, A. L.; Mestan, J.; Daley, G. Q.; Callahan, L.; Catley, L.; Cavazza, C.; Azam, M.; Neuberg, D.; Wright, R. D.; Gilliland, D. G.; Griffin, J. D. Characterization of AMN107, a selective inhibitor of native and mutant BCR-ABL. Cancer Cell 2005, 7 (2), 129-141.
25. Golemovic, M.; Verstovsek, S.; Giles, F.; Cortes, J.; Manshouri, T.; Manley, P. W.; Mestan, J.; Dugan, M.; Alland, L.; Griffin, J. D.; Arlinghaus, R. B.; Sun, T.; Kantarjian, H.; Beran, M. AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia. Clin. Cancer Res. 2005, 11 (13), 4941-4947.
26. Bradeen, H. A.; Eide, C. A.; O'Hare, T.; Jonhson, K. J.; Willis, S. G.; Lee, F. Y.; Druker, B. J.; Deininger, M. W. Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood 2006, 108 (7), 2332-2338.
27. Ray, A.; Cowan-Jacob, S. W.; Manley, P. W.; Mestan, J.; Griffin, J. D. Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study. Blood 2007, 109 (11), 5011-5015.
28. Hughes, T.; Saglio, G.; Branford, S.; Soverini, S.; Kim, D. W.; Müller, M. C.; Martinelli, G., Cortes, J.; Beppu, L.; Gottardi, E.; Kim, D.; Erben, P.; Shou, Y.; Haque, A.; Gallagher, N.; Radich, J.; Hochhaus, A. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. J. Clin. Oncol. 2009, 27 (25), 4204-4210.
29. Weisberg, E.; Catley, L.; Wright, R. D.; Moreno, D.; Banerji, L.; Ray, A.; Manley, P. W.; Mestan, J.; Fabbro, D.; Jiang, J.; Hall-Meyers, E.; Callahan, L.; DellaGatta, J. L.; Kung, A. L.; Griffin, J. D. Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias. Blood 2007, 109 (5), 2112-2120.
30. White, D. L.; Saunders, V. A.; Quinn, S. R.; Manley, P. W.; Hughes, T. P. Imatinib increases the intracellular concentration of nilotinib, which may explain the observed synergy between these drugs. Blood 2007, 109 (8), 3609-3610.
31. Brendel, C.; Scharenberg, C.; Dohse, M.; Robey, R. W.; Bates, S. E.; Shukla, S.; Ambudkar, S. V.; Wang, Y.; Wennemuth, G.; Burchert, A.; Boudriot, U.; Neubauer, A. Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells. Leukemia 2007, 21 (6), 1267-1275.
32. Hegedus, C.; Ozvegy-Laczka, C.; Apati, A.; Magócsi, M.; Német, K.; Orfi, L.; Kéri, G.; Katona, M.; Takáts, Z.; Váradi, A.; Szakács, G.; Sarkadi, B. Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. Br. J. Pharmacol. 2009, 158 (4), 1153-1164.
33. Davies, A.; Jordanides, N. E.; Giannoudis, A.; Lucas, C. M.; Hatziieremia, S.; Harris, R. J.; Jørgensen, H. G.; Holyoake, T. L.; Pirmohamed, M.; Clark, R. E.; Mountford, J. C. Nilotinib concentration in cell lines and primary CD34+ chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters. Leukemia 2009, 23 (11), 1999-2006.
34. Giles, F. J.; O'Dwyer, M.; Swords, R. Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia 2009, 23, 1698-1707.
35. Kantarjian, H. M.; Giles, F. J.; Bhalla, K. N.; Pinilla-Ibarz, J.; Larson, R. A.; Gattermann, N.; Ottmann, O. G.; Hochhaus, A.; Radich, J. P.; Saglio, G.; Hughes, T. P.; Martinelli, G.; Kim, D. W.; Shou, Y.; Gallagher, N. J.; Blakesley, R.; Baccarani, M.; Cortes, J.; le Coutre, P. D. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood 2011, 117 (4), 1141-1145.
36. Cortes, J. E.; Jones, D.; O'Brien, S.; Jabbour, E.; Ravandi, F.; Koller, C.; Borthakur, G.; Walker, B.; Zhao, W.; Shan, J.; Kantarjian, H. Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J. Clin. Oncol. 2010, 28 (3), 398-404.
37. Kantarjian, H.; Shah, N. P.; Hochhaus, A.; Cortes, J.; Shah, S.; Ayala, M.; Moiraghi, B.; Shen, Z.; Mayer, J.; Pasquini, R.; Nakamae, H.; Huguet, F.; Boqué, C.; Chuah, C.; Bleickardt, E.; Bradley-Garelik, M. B.; Zhu, C.; Szatrowski, T.; Shapiro, D.; Baccarani, M. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 2010, 362 (24), 2260-2270.
38. Kantarjian, H. M.; Shah, N. P.; Cortes, J. E.; Baccarani, M.; Agarwal, M. B.; Undurraga, M. S.; Wang, J.; Kassack Ipina, J. J.; Kim, D. W.; Ogura, M.; Pavlosky, C.; Junghanss, C.; Milone, J. H.; Nicolini, F. E.; Robak, T.; van Droogenbroeck, J.; Vellenga, E.; Bradley-Garelik, M. B.; Zhu, C.; Hochhaus, A. Dasatinib or imatinib in newly diagnosed chronic phase chronic myeloid leukemia: 2-year follow up from a randomized phase 3 trial (DASISION). Blood 2011, Dec 9 [Epub ahead of print].
39. Cortes, J. E.; Jones, D.; O'Brien, S.; Jabbour, E.; Konopleva, M.; Ferrajoli, A.; Kadia, T.; Borthakur, G.; Stigliano, D.; Shan, J.; Kantarjian, H. Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. J. Clin. Oncol. 2010, 28 (3), 392-397.
40. Kantarjian, H. M.; Hochhaus, A.; Saglio, G.; De Souza, C.; Flinn, I. W.; Stenke, L.; Goh, Y. T.; Rosti, G.; Nakamae, H.; Gallagher, N. J.; Hoenekopp, A.; Blakesley, R. E.; Larson, R. A.; Hughes, T. P. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol. 2011, 12 (9), 841-851.